Clinical trials: Cervix Cancer
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
This phase II trial is studying how well giving bevacizumab together with radiation therapy and cisplatin works in treating patients with previously untreated locally advanced cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7
- Trial name
- NCT00369122
- Testing
- Bevacizumab, Cisplatin, External Beam Radiation Therapy
- Where
- 106 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Infection
Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs
UCLA and Northeast Valley Health Center (NEVHC), a large, multi-site Federally Qualified Health Center (FQHC), are partnering to address underutilization of the prophylactic HPV vaccine among underserved, ethnic minority…
- Trial name
- NCT03726151
- Testing
- Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
- Where
- 7 sites in United States
- Volunteers
- 17,000 people
- Sponsor
- University of California, Los Angeles
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Uterine Cervical Dysplasia, Uterine Cervical Intraepithelial Neoplasia
Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix
This study tested the safety and performance of a new cell collector device and compared the results to those obtained with the current existing device that are being used routinely
- Conditions
- Uterine Cervical Dysplasia, Uterine Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasia, Uterine Cervical Cancer
- Trial name
- NCT00266084
- Volunteers
- 85 people
- Sponsor
- University Hospitals Cleveland Medical Center
Cervical Cancer, Endometrial Cancer
Pelvic Fractures and Radiation Therapy for Cervical Cancer
The goal of this study is to estimate how often pelvic fractures occur in women treated with radiation therapy for either newly diagnosed or recurrent cervical, endometrial, or vaginal cancer.
- Conditions
- Cervical Cancer, Endometrial Cancer, Vaginal Cancer
- Trial name
- NCT00800644
- Testing
- CT or MRI + Blood Test
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- M.D. Anderson Cancer Center
Evaluation of New Tissue Biomarkers for Cervical Cancer
Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions
The following trial is a multicenter and prospective research trial of the colposcopy unit of luebeck university and the national research center in Borstel, Germany.
- Trial name
- NCT02238990
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Luebeck
Cervical Cancer
SElf-SAMpling in Cervical Cancer Screening; SESAM Study
Study aims to support development of evidence based health care in Norway through evaluating recently proposed technological improvements in cervical cancer control before their routine use.
- Trial name
- SESAM (NCT02945891)
- Testing
- HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens
- Where
- 4 sites in Norway
- Volunteers
- 310 people
- Sponsor
- Oslo University Hospital
Cervical Cancer
Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01158248
- Testing
- panitumumab, cisplatin, brachytherapy
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University Innsbruck
Cervical Intraepithelial Neoplasia, Cervical Cancer
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
This is a bridging trial of the recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.The primary objective of this study is to evaluate the immunogenicity (type specific IgG antibody) and safety…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT02562508
- Testing
- 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine
- Where
- China
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Cervical Cancer, Cervical Intraepithelial Neoplasm
The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients
This study will elucidate the role of 3D transvaginal ultrasound in assessing (1) cervical vascularity and blood flow in patients with cervical cancer and cervical intraepithelial neoplasm, and (2) tumor vascularity and blood…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasm, Ovarian Cancer
- Trial name
- NCT07385976
- Testing
- Doppler ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Far Eastern Memorial Hospital
Human Papillomavirus, Uterine Cervical Neoplasms
An HPV Vaccine Provider Intervention in Safety Net Clinics
The purpose of this study is to develop, deliver and evaluate a provider intervention for mothers and their children to encourage receipt of the human papillomavirus (HPV) vaccine in the children and appropriate cervical cancer…
- Trial name
- NCT02808832
- Testing
- Educational materials
- Where
- United States
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
Cervical Cancer, Anogenital Warts
Evaluation of Long Term Immunity Following HPV Vaccination
In Fiji, cervical cancer is the second most frequent cancer and the highest cause of cancer mortality in women. In 2008/9, the Ministry of Health in Fiji accepted a donation of 110,000 doses of quadrivalent HPV vaccine, Gardasil®…
- Trial name
- NCT02276521
- Testing
- Cervarix®
- Where
- Fiji
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Cervical Cancer
Extraperitoneal Lymph Node Dissection in Patients With Cervical Cancer
Primary Objectives: To determine the feasibility of performing an extraperitoneal laparoscopic lymphadenectomy in patients with stage IB2-IVA cervical carcinoma who are dispositioned to undergo radiotherapy and concurrent…
- Trial name
- NCT00500435
- Testing
- Extraperitoneal Laparoscopic Lymphadenectomy
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
Single Application Brachytherapy in Cervical Cancer
The purpose of the study is to evaluate safety and feasibility of single brachytherapy application with dose delivery in multiple fractions.
- Trial name
- NCT03110497
- Testing
- Single application multi-fraction brachytherapy
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Tata Memorial Hospital
Cervical Cancer
Evaluation of the Cancer Tracking System (CATSystem)
Cervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent…
- Trial name
- CATSystem (NCT06286462)
- Testing
- Cancer Tracking System (CATSystem)
- Where
- 10 sites in Kenya
- Volunteers
- 6,600 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Gynecologic Malignant Tumor
The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor
As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies.
- Trial name
- NCT02166515
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhiqing, Liang
Preterm Birth, Pregnancy Trimester, Second
Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial
The aim of our study is to evaluate the effect of use of prophylactic vaginal progesterone on the incidence of severe preterm delivery, defined as delivery before 33+6 weeks in women with a short cervical length of 15mm.
- Trial name
- NCT00422526
- Testing
- Micronised progesterone (Utrogestan)
- Where
- 8 sites in Brazil, Chile and 2 more
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Cervical Cancer, Papillomavirus Infections
DNA Methylation and the Increased Risk of Cervical Cancer Development
This study aims to investigate the correlation between reproductive tract microbiota and DNA methylation in cervical epithelial cells, as well as its impact on the development of cervical cancer, through a paired case-control…
- Trial name
- NCT06859151
- Testing
- Reproductive tract microbiota
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Cervical Cancer, Endometrial Cancer
Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer
RATIONALE: The use of pelvic drains may help to prevent complications following radical hysterectomy and pelvic lymphadenectomy.
- Conditions
- Cervical Cancer, Endometrial Cancer, Infection, Perioperative/Postoperative Complications
- Trial name
- NCT00003267
- Testing
- infection prophylaxis and management, management of therapy complications, surgical procedure
- Where
- 18 sites in Austria, Belgium and 6 more
- Volunteers
- 214 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cervical Cancer, Cervical Precancerous Lesions
Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
The primary study hypothesis wasthat a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent HPV infection and cervical…
- Trial name
- NCT00923702
- Testing
- Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
- Where
- 8 sites in India
- Volunteers
- 22,729 people, healthy volunteers welcome
- Sponsor
- Partha Basu